Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADALAT vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
>99% bound to albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
4.9 L/kg (high distribution into tissues).
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
Oral: 87% (tablet and solution); IM: 100%.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
None
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Known hypersensitivity to aripiprazole or any of its excipients.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADALAT vs ABILIFY, answered by our medical review team.
ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADALAT and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADALAT and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.